Tarsus Pharmaceuticals (TARS) PT Raised to $63 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Wall Street ends choppy session lower as tech shares drop
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
- Oil prices fall 1% to 4-month lows as progress in US-Iran talks cools supply concerns
- Trump discloses over $1.4 billion in crypto income in 2025 filing
Tarsus Pharmaceuticals (TARS) PT Raised to $60 at Barclays
May 10, 2024 3:29 AM EDTBarclays analyst Balaji Prasad raised the price target on Tarsus Pharmaceuticals (NASDAQ: TARS) to $60.00 (from $50.00) while maintaining a Overweight rating.... More
Tarsus Pharmaceuticals (TARS) PT Raised to $61 at Oppenheimer
May 9, 2024 7:36 AM EDTOppenheimer analyst Francois Brisebois raised the price target on Tarsus Pharmaceuticals (NASDAQ: TARS) to $61.00 (from $59.00) while maintaining a Outperform rating.... More
Tarsus Pharmaceuticals, Inc. (TARS) Tops Q1 EPS by 17c
May 8, 2024 5:13 PM EDTTarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q1 EPS of ($1.01), $0.17 better than the analyst estimate of ($1.18). Revenue for the quarter came in at $27.61 million versus the consensus estimate of $17.5 million.
For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.
... More